Who makes Fluzone I®ntradermal vaccine, 2014-2015 formulation?

Fluzone I®ntradermal vaccine, 2014-2015 formulation is developed by Sanofi Pasteur, a Sanofi Company.

What development phase is Fluzone I®ntradermal vaccine, 2014-2015 formulation in?

Fluzone I®ntradermal vaccine, 2014-2015 formulation is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

Fluzone I®ntradermal vaccine, 2014-2015 formulation

Sanofi Pasteur, a Sanofi Company · FDA-approved active Biologic Quality 2/100

At a glance

Generic name	Fluzone I®ntradermal vaccine, 2014-2015 formulation
Also known as	Fluzone® Intradermal vaccine
Sponsor	Sanofi Pasteur, a Sanofi Company
Modality	Biologic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fluzone I®ntradermal vaccine, 2014-2015 formulation CI brief — competitive landscape report
Fluzone I®ntradermal vaccine, 2014-2015 formulation updates RSS · CI watch RSS
Sanofi Pasteur, a Sanofi Company portfolio CI